EOLS · Evolus, Inc.
Market Cap
$517.84M
Shares
66.05M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.84
Open$8.01
Day$7.81–8.15
52W close$3.94–9.30
Avg vol 30d1.1M
Short int5.4M · 8.1% float · 5.2d
Short vol69%
Last earningsAug 5, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 6, 2026
Est · unconfirmed
· in 8 wks
filed Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$316.49M
Trailing 12 months
Net income (TTM)
−$34.33M
Trailing 12 months
Revenue growth YoY
+21.2%
Year over year
Operating margin
-5.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-3.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$111.57M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.2%
Year over year · more shares
Price change (1Y)
+4.4%
Trailing year
Short interest
8.1%
Latest settlement · 5.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+29%
above
Price vs 50-day avg
+6%
above
RSI (14)
43
neutral
MACD trend
Negative
52-week position
73%
mid-range
Momentum
relative strength
1-month return
−2%
trailing
6-month return
+69%
trailing
YTD return
+18%
this year
Relative strength
+51%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +32 funds added
Insider flow
Distributing
Net -$950.0K over 90 days · 100% sells
Short interest
Falling
8.13% of float · ▼ -8.3% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
160 holders — mid 3-yr range
Squeeze score
69
elevated · 0–100
Fundamentals
Revenue growth
+12%
Y/Y
Gross margin
66%
contracting
EPS growth
+1%
Y/Y
Free cash flow
$-45.7M
Balance sheet
$92.3M
net debt
Quant / Vol
risk profile
Volatility
67%
annualized · 1-yr
Max drawdown
−48%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
full-year 2026
Total net revenues
Initiated
$330M – $337M
prior FY $297.18M
midpoint +12.2% Y/Y
Adjusted gross profit margin
Non-GAAP
Initiated
67% – 67.5%
Evolysse® and Estyme® injectable HA gels contribution to total r
Initiated
10% – 12%
Non-GAAP operating expenses
Non-GAAP
Initiated
$212M – $216M
full-year 2028
Total net revenue
Initiated
$450M – $500M
prior FY $297.18M
midpoint +59.8% Y/Y
Adjusted EBITDA margin
Non-GAAP
Initiated
13% – 15%
Prior guidance
period ended
· from the 8-K filed Jul 31, 2024
Total net revenues
· full year 2024
$260M – $270M
Adjusted gross profit margin
· full year 2024
68% – 71%
Non-GAAP operating expenses
· full year 2024
$185M – $190M
Guided vs delivered
· last 1 settled
Total net revenues
full year 2024
guided $260M – $270M
$266.27M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+29%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
73%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +32 funds added
Insider flow
Distributing
Net -$950.0K over 90 days · 100% sells
Short interest
Falling
8.13% of float · ▼ -8.3% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
160 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4
Now $8 · 73%
Range high $9
vs 200-day avg +29%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EOLS
this stock
Evolus, Inc.
|
$517.84M | +17.9% | +11.6% | — | 8.1% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.31B | +17.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$44.03B | -8.9% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$43.22B | +18.8% | +4.3% | 60.8 | 3.2% |
|
HLN
Haleon plc
|
$40.41B | -9.1% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EOLS | -13.4% | -2.2% | +69.0% | -13.8% | +17.9% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -12.2% | -0.5% | +51.1% | -13.4% | +5.8% |
Key facts
CIK
1570562
CUSIP
30052C107
13F (30d)
83 filings
83 filers
Visit website
Investor relations